Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › abemaciclib

abemaciclib

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of abemaciclib

25 trials tracked of abemaciclib: 1 in phase 3 or 4.

25Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 2 12 Phase 1 12
  1. Phase 4 A Study of Abemaciclib in Indian Women With Advanced Breast Cancer Completed
  2. Phase 2 A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain Completed
  3. Phase 2 A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma Completed
  4. Phase 2 Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Completed
  5. Phase 2 A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Completed
  6. Phase 2 Study of LY2835219 for Mantle Cell Lymphoma Completed
Show 19 more trials
  1. Phase 2 A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer Completed
  2. Phase 2 A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer Completed
  3. Phase 2 A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer Completed
  4. Phase 2 A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer Completed
  5. Phase 2 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Completed
  6. Phase 2 A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Completed
  7. Phase 2 Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer Completed
  8. Phase 1 A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment Completed
  9. Phase 1 A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food Completed
  10. Phase 1 ABEMA Alone or in COMBO With MK-6482 Completed
  11. Phase 1 A Phase 1 Study of LY2835219 In Participants With Advanced Cancer Completed
  12. Phase 1 A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants Completed
  13. Phase 1 A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers Completed
  14. Phase 1 This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer Completed
  15. Phase 1 A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body Completed
  16. Phase 1 A Study of LY2835219 in Participants With Cancer Completed
  17. Phase 1 A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) Completed
  18. Phase 1 A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Completed
  19. Phase 1 A Study of Abemaciclib in Healthy Participants Completed

Showing the 25 most-cited and recently-updated of 25 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
CDK4/6 inhibitors show therapeutic potential in advanced gastrointestinal cancers, review finds
Infectious Disease Sys. Review
CDK4/6 inhibitors show therapeutic potential in advanced gastrointestinal cancers, review finds CDK4/6 inhibitors show promise against digestive cancers
This narrative review examines the role of CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) in advanced gastrointestinal cancers. It…
New review reveals how CDK4/6 drugs might work against stomach, colon, and liver cancers, but hurdles remain.
Frontiers Jun 5, 2026
Meta-analysis of CDK4/6 inhibitor rechallenge shows improved progression-free survival in advanced breast cancer
Oncology Meta-analysis
Meta-analysis of CDK4/6 inhibitor rechallenge shows improved progression-free survival in advanced breast cancer Switching drugs offers hope for advanced breast cancer patients facing treatment failure
This meta-analysis synthesizes data from phase II and III clinical trials involving 1396 patients with hormone receptor-positive, HER2-negat…
A large review found that restarting a specific cancer drug after stopping it can delay disease growth by nearly two months compared to stan…
May 28, 2026
CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer
Oncology Meta-analysis
CDK4/6 inhibitors plus endocrine therapy improve survival in advanced hormone receptor-positive breast cancer CDK4/6 Inhibitors Boost Survival In Advanced Breast Cancer
This meta-analysis of 11 phase 3 trials involving 6035 patients demonstrates that CDK4/6 inhibitors combined with endocrine therapy signific…
New data shows adding CDK4/6 inhibitors to hormone therapy helps patients live longer with advanced breast cancer.
May 1, 2026
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma
Genetics & Precision Medicine Phase I
Genomically tailored multiagent regimen shows limited efficacy in recurrent glioblastoma Personalized drug combos extend life in brain cancer
This phase I trial tested a genomically tailored multiagent regimen in 30 adults with recurrent glioblastoma. Median overall survival was 12…
A new approach using tailored drug combinations is helping some patients with recurring brain cancer live longer, offering fresh hope where …
May 1, 2026
CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC
Drug Pipeline Cohort
CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC Two drugs linked to longer survival than palbociclib in breast cancer
This retrospective single-center analysis of 341 patients with HR+/HER2− MBC found that palbociclib, abemaciclib, and dalpiciclib combined w…
In a real-world analysis, two CDK4/6 inhibitors showed longer survival times than palbociclib for metastatic breast cancer patients.
Frontiers Apr 24, 2026
Imlunestrant shows OS benefit in ESR1-mutated advanced breast cancer in Phase III trial
OB/GYN & Women's Health RCT
Imlunestrant shows OS benefit in ESR1-mutated advanced breast cancer in Phase III trial A New Pill Combo Helps Women with Advanced Breast Cancer Live Longer
A Phase III RCT of 874 endocrine-pretreated ER+/HER2- advanced breast cancer patients found imlunestrant monotherapy improved median OS vers…
A new pill combo helps women with advanced breast cancer live longer and delays the need for harsh chemotherapy.
Apr 12, 2026